🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)Tirzepatide and cholesterol — looking for input

Tirzepatide and cholesterol — looking for input

wei_SG Mon, Jan 20, 2025 at 4:31 PM 44 replies 2,688 viewsPage 1 of 9
This thread is more than 16 months old. Information may be outdated. Consider searching for more recent discussions.
wei_SG
Member
234
890
Nov 2024
Singapore, SG
Jan 20, 2025 at 4:31 PM#1

Posting this because the summary going around does not say what the paper says, and the difference matters for how people here are using it.

ApoB is the more informative number and it is cheap. LDL-C estimates cholesterol mass in atherogenic particles; ApoB counts the particles, and it is particle count that tracks risk — which is why the two can disagree and why the disagreement is the clinically interesting case. Triglycerides fall substantially with weight loss and improved insulin sensitivity, HDL moves modestly, and LDL-C often barely moves at all, which surprises people who expected everything to improve together.

Where I think it is weakest: the population was selected and supported in ways a real cohort is not, so I would read the effect size as a ceiling rather than an expectation.

So the question, as narrowly as I can put it: whether an unchanged LDL-C alongside a large triglyceride fall is a good result or a bad one, because ApoB and LDL-C seem to be telling different stories. Practical detail welcome, however dull — the duller the better.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
7 10WendyG_ATL, SaraMom3, Dr.MetabolicMD and 4 others
Reply Quote Save Share Report
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Jan 20, 2025 at 4:49 PM#2
wei_SG said:
ApoB is the more informative number and it is cheap.

True, though the ladder is longer and that is not a neutral detail — six dose steps means six opportunities to stall on the way up, and plenty of people never reach the dose the headline number came from.

8 11HPLC_Greg, LibrarianMeg, bri_stats and 5 others
Reply Quote Save Share Report
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
Jan 20, 2025 at 5:07 PM#3
wei_SG said:
ApoB is the more informative number and it is cheap.

Careful with treating an unchanged LDL-C as a failure. If ApoB and triglycerides both fell, the particle picture improved regardless of what the calculated LDL says.

9 12lori_vegas, Dr.PulmRoch, maya_sedona and 6 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
LipidDoc_ATL
Senior Member
1,123
5,678
Apr 2024
Atlanta, GA
Jan 20, 2025 at 5:25 PM#4

Answering the narrow version, because the broad one does not have a single answer. Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five. That matters when you are deciding whether a dose step has finished expressing itself.

Last edited: Jan 20, 2025 at 10:25 PM
10 13DebRD_ATL, KristenIndy, MarkLI_maint and 7 others
Reply Quote Save Share Report
EndoResFellow
Member
456
2,345
Sep 2024
Baltimore, MD
Jan 20, 2025 at 7:01 PM#5
labquiet_amy said:
True, though the ladder is longer and that is not a neutral detail — six dose steps means six opportunities to stall on the way up, and plenty of…

This matches mine closely enough to be worth saying so out loud.

Last edited: Jan 20, 2025 at 9:01 PM
11 14Dr.ObesityLA, NurseKim_ATL, paul_denver and 8 others
Reply Quote Save Share Report
1239

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register